Sectors & Industries HealthcareDiagnostics & Research
Best Diagnostic & Research Stocks to Buy Now (2024)
Top diagnostic & research stocks in 2024 ranked by overall Zen Score. See the best diagnostic & research stocks to buy now, according to analyst forecasts for the diagnostics & research industry.

Industry: Diagnostics & Research

Overview Zen Score Price Valuation Financials Forecast

Earnings & Revenue Dividends Ownership Technicals

Ticker	Company	Market Cap	Price	Price Target	Upside/Downside	Consensus	Analysts	Fore. Revenue Growth	Fore. Earnings Growth	Forecast ROE	Forecast ROA
FONR	FONAR CORP	$118.18M	$17.61	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ICLR	ICON PLC	$26.06B	$315.14	$344.38	9.28%	Strong Buy	8	6.04%	31.77%	N/A	N/A
STRR	STAR EQUITY HOLDINGS INC	$14.58M	$0.92	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
RVTY	REVVITY INC	$12.70B	$102.82	$118.89	15.63%	Buy	9	4.45%	21.89%	N/A	N/A
CRL	CHARLES RIVER LABORATORIES INTERNATIONAL INC	$12.08B	$235.27	$264.00	12.21%	Buy	7	4.97%	47.49%	N/A	N/A
NEOG	NEOGEN CORP	$2.63B	$12.14	$17.00	40.03%	Hold	1	0.76%	526.68%	6.20%	4.25%
TMO	THERMO FISHER SCIENTIFIC INC	$218.93B	$573.55	$628.20	9.53%	Buy	10	4.13%	56.87%	N/A	N/A
IDXX	IDEXX LABORATORIES INC	$39.38B	$476.87	$593.75	24.51%	Strong Buy	4	8.72%	7.44%	N/A	N/A
ENZ	ENZO BIOCHEM INC	$54.81M	$1.07	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
DGX	QUEST DIAGNOSTICS INC	$15.07B	$135.64	$148.78	9.69%	Buy	9	2.82%	14.83%	N/A	N/A
QGEN	QIAGEN NV	$9.53B	$42.58	$50.66	18.99%	Buy	5	5.09%	26.17%	N/A	N/A
SHC	SOTERA HEALTH CO	$3.20B	$11.29	$16.38	45.04%	Strong Buy	4	1.95%	547.37%	N/A	N/A
A	AGILENT TECHNOLOGIES INC	$41.21B	$140.61	$139.67	-0.67%	Buy	12	3.35%	35.95%	N/A	N/A
DHR	DANAHER CORP	$183.25B	$247.40	$278.30	12.49%	Strong Buy	10	7.40%	57.06%	N/A	N/A
MEDP	MEDPACE HOLDINGS INC	$12.42B	$400.74	$448.60	11.94%	Strong Buy	5	12.68%	0.10%	N/A	N/A
FLGT	FULGENT GENETICS INC	$643.07M	$21.49	$30.00	39.60%	Hold	2	5.61%	N/A	N/A	N/A
WAT	WATERS CORP	$18.94B	$319.86	$300.83	-5.95%	Hold	6	3.45%	29.72%	N/A	N/A
LH	LABORATORY CORP OF AMERICA HOLDINGS	$16.95B	$201.04	$245.50	22.12%	Buy	6	5.12%	113.65%	N/A	N/A
SERA	SERA PROGNOSTICS INC	$321.66M	$9.92	N/A	N/A	N/A	N/A	47.06%	N/A	N/A	N/A
PRE	PRENETICS GLOBAL LTD	$70.55M	$5.78	$9.00	55.71%	Strong Buy	1	N/A	N/A	N/A	N/A
CSTL	CASTLE BIOSCIENCES INC	$673.89M	$24.41	$31.00	27.00%	Strong Buy	4	-5.28%	N/A	N/A	N/A
IQV	IQVIA HOLDINGS INC	$41.37B	$227.04	$265.67	17.01%	Strong Buy	9	5.86%	30.00%	N/A	N/A
PSNL	PERSONALIS INC	$80.30M	$1.59	$3.75	135.85%	Strong Buy	2	22.09%	N/A	N/A	N/A
PRPO	PRECIPIO INC	$8.55M	$5.98	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NTRA	NATERA INC	$11.74B	$97.21	$90.83	-6.56%	Strong Buy	12	22.47%	N/A	N/A	N/A
MTD	METTLER TOLEDO INTERNATIONAL INC	$26.87B	$1,250.80	$1.18k	-6.06%	Hold	5	3.63%	29.61%	N/A	N/A
DRIO	DARIOHEALTH CORP	$47.11M	$1.60	$4.00	150.00%	Strong Buy	1	34.89%	N/A	N/A	N/A
OLK	OLINK HOLDING AB (PUBL)	$2.88B	$23.15	$26.00	12.31%	Hold	2	24.72%	N/A	N/A	N/A
ACRS	ACLARIS THERAPEUTICS INC	$92.91M	$1.31	$5.00	281.68%	Buy	2	-29.88%	N/A	N/A	N/A
STIM	NEURONETICS INC	$111.59M	$3.75	$8.00	113.33%	Strong Buy	1	10.95%	N/A	N/A	N/A
DMTK	DERMTECH INC	$21.71M	$0.63	$1.38	119.62%	Buy	3	29.45%	N/A	-105.97%	-49.69%
NEO	NEOGENOMICS INC	$1.98B	$15.51	$20.00	28.95%	Strong Buy	8	8.78%	N/A	N/A	N/A
TWST	TWIST BIOSCIENCE CORP	$2.60B	$44.67	$45.60	2.08%	Strong Buy	5	12.78%	N/A	N/A	N/A
EXAS	EXACT SCIENCES CORP	$11.50B	$63.35	$92.75	46.41%	Strong Buy	4	13.49%	N/A	N/A	N/A
OCX	ONCOCYTE CORP	$22.92M	$2.77	$4.06	46.68%	Buy	4	N/A	N/A	113.17%	30.93%
BNR	BURNING ROCK BIOTECH LTD	$83.28M	$0.81	N/A	N/A	N/A	N/A	N/A	N/A	-73.25%	-54.12%
BGLC	BIONEXUS GENE LAB CORP	$10.51M	$0.60	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
RDNT	RADNET INC	$3.56B	$52.00	$53.67	3.21%	Strong Buy	3	8.05%	960.00%	N/A	N/A
APDN	APPLIED DNA SCIENCES INC	$3.08M	$3.63	$40.00	1,001.93%	Buy	1	4.14%	N/A	N/A	N/A
LAB	STANDARD BIOTOOLS INC	$719.49M	$2.48	$3.38	36.09%	Strong Buy	2	35.69%	N/A	N/A	N/A
GH	GUARDANT HEALTH INC	$2.32B	$19.10	$34.00	78.01%	Strong Buy	7	21.15%	N/A	N/A	N/A
XGN	EXAGEN INC	$23.79M	$1.38	N/A	N/A	N/A	N/A	3.33%	N/A	N/A	N/A
XWEL	XWELL INC	$7.53M	$1.80	$7.00	288.89%	Buy	1	N/A	N/A	N/A	N/A
BDSX	BIODESIX INC	$147.35M	$1.52	$3.50	130.26%	Strong Buy	1	32.42%	N/A	N/A	N/A
CDNA	CAREDX INC	$527.11M	$10.18	$15.00	47.35%	Strong Buy	2	-4.75%	N/A	N/A	N/A
ME	23ANDME HOLDING CO	$235.18M	$0.49	$0.47	-3.49%	Hold	1	6.26%	N/A	N/A	N/A
CHEK	CHECK-CAP LTD	$12.89M	$2.20	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ULS	UL SOLUTIONS INC	N/A	$36.07	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PRPH	PROPHASE LABS INC	$96.36M	$5.34	$11.00	105.99%	Buy	1	65.50%	N/A	N/A	N/A
OPK	OPKO HEALTH INC	$920.03M	$1.32	$3.17	139.92%	Strong Buy	3	0.94%	N/A	N/A	N/A
AWH	ASPIRA WOMEN's HEALTH INC	$39.62M	$3.21	$3.30	2.80%	Hold	1	16.89%	N/A	N/A	N/A
NDRA	ENDRA LIFE SCIENCES INC	$3.56M	$0.32	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NOTV	INOTIV INC	$123.02M	$4.77	$18.25	282.60%	Strong Buy	2	-1.09%	N/A	N/A	N/A
VNRX	VOLITIONRX LTD	$63.93M	$0.78	$3.50	349.29%	Strong Buy	2	N/A	N/A	N/A	N/A
MDXH	MDXHEALTH SA	$8.54M	$3.13	$7.50	139.62%	Strong Buy	2	11.69%	N/A	N/A	N/A
MYGN	MYRIAD GENETICS INC	$1.79B	$19.97	$22.00	10.17%	Buy	4	8.80%	N/A	N/A	N/A
GENE	GENETIC TECHNOLOGIES LTD	$549.39k	$2.38	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ISPC	ISPECIMEN INC	$2.51M	$0.28	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
BIAF	BIOAFFINITY TECHNOLOGIES INC	$22.68M	$1.97	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ILMN	ILLUMINA INC	$18.95B	$118.98	$151.20	27.08%	Buy	10	4.80%	N/A	N/A	N/A
PMD	PSYCHEMEDICS CORP	$14.59M	$2.54	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TRIB	TRINITY BIOTECH PLC	$13.26M	$1.73	N/A	N/A	N/A	N/A	17.89%	N/A	N/A	N/A
MYNZ	MAINZ BIOMED NV	$15.66M	$0.74	$3.00	305.41%	Buy	1	N/A	N/A	N/A	N/A
MMA	ALTA GLOBAL GROUP LTD	N/A	$3.27	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CNTG	CENTOGENE NV	$12.42M	$0.45	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TTOO	T2 BIOSYSTEMS INC	$31.92M	$3.63	$3.00	-17.36%	Hold	1	N/A	N/A	N/A	N/A

Diagnostic & Research Stocks FAQ

What are the best diagnostic & research stocks to buy right now in May 2024?

According to Zen Score, the 3 best diagnostic & research stocks to buy right now are:

1. Fonar (NASDAQ:FONR)

Fonar (NASDAQ:FONR) is the top diagnostic & research stock with a Zen Score of 47, which is 20 points higher than the diagnostic & research industry average of 27. It passed 14 out of 33 due diligence checks and has strong fundamentals. Fonar has seen its stock return 6.6% over the past year, overperforming other diagnostic & research stocks by 5 percentage points.

2. Icon (NASDAQ:ICLR)

Icon (NASDAQ:ICLR) is the second best diagnostic & research stock with a Zen Score of 47, which is 20 points higher than the diagnostic & research industry average of 27. It passed 15 out of 33 due diligence checks and has strong fundamentals. Icon has seen its stock return 66.03% over the past year, overperforming other diagnostic & research stocks by 64 percentage points.

Icon has an average 1 year price target of $344.38, an upside of 9.28% from Icon's current stock price of $315.14.

Icon stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 8 analysts covering Icon, 75% have issued a Strong Buy rating, 25% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

3. Star Equity Holdings (NASDAQ:STRR)

Star Equity Holdings (NASDAQ:STRR) is the third best diagnostic & research stock with a Zen Score of 46, which is 19 points higher than the diagnostic & research industry average of 27. It passed 18 out of 38 due diligence checks and has strong fundamentals. Star Equity Holdings has seen its stock return 8.24% over the past year, overperforming other diagnostic & research stocks by 7 percentage points.

What are the diagnostic & research stocks with highest dividends?

Out of 7 diagnostic & research stocks that have issued dividends in the past year, the 3 diagnostic & research stocks with the highest dividend yields are:

1. Qiagen Nv (NYSE:QGEN)

Qiagen Nv (NYSE:QGEN) has an annual dividend yield of 3.01%, which is 2 percentage points higher than the diagnostic & research industry average of 1.37%.

Qiagen Nv's dividend payout ratio of 87.2% indicates that its dividend yield is sustainable for the long-term.

2. Quest Diagnostics (NYSE:DGX)

Quest Diagnostics (NYSE:DGX) has an annual dividend yield of 2.12%, which is 1 percentage points higher than the diagnostic & research industry average of 1.37%. Quest Diagnostics's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Quest Diagnostics's dividend has shown consistent growth over the last 10 years.

Quest Diagnostics's dividend payout ratio of 38.2% indicates that its dividend yield is sustainable for the long-term.

3. Laboratory Of America Holdings (NYSE:LH)

Laboratory Of America Holdings (NYSE:LH) has an annual dividend yield of 1.43%, which is the same as the diagnostic & research industry average of 1.37%. Laboratory Of America Holdings's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Laboratory Of America Holdings's dividend has not shown consistent growth over the last 10 years.

Laboratory Of America Holdings's dividend payout ratio of 56.5% indicates that its dividend yield is sustainable for the long-term.

Why are diagnostic & research stocks up?

Diagnostic & research stocks were up 0.47% in the last day, and down -0.04% over the last week.

We couldn't find a catalyst for why diagnostic & research stocks are up.

What are the most undervalued diagnostic & research stocks?

Based on WallStreetZen's Valuation Score, the 3 most undervalued diagnostic & research stocks right now are:

1. Star Equity Holdings (NASDAQ:STRR)

Star Equity Holdings (NASDAQ:STRR) is the most undervalued diagnostic & research stock based on WallStreetZen's Valuation Score. Star Equity Holdings has a valuation score of 71, which is 53 points higher than the diagnostic & research industry average of 18. It passed 5 out of 7 valuation due diligence checks.

Star Equity Holdings's stock has gained 8.24% in the past year. It has overperformed other stocks in the diagnostic & research industry by 7 percentage points.

2. Enzo Biochem (NYSE:ENZ)

Enzo Biochem (NYSE:ENZ) is the second most undervalued diagnostic & research stock based on WallStreetZen's Valuation Score. Enzo Biochem has a valuation score of 71, which is 53 points higher than the diagnostic & research industry average of 18. It passed 5 out of 7 valuation due diligence checks.

Enzo Biochem's stock has dropped -57.87% in the past year. It has underperformed other stocks in the diagnostic & research industry by -59 percentage points.

3. Fonar (NASDAQ:FONR)

Fonar (NASDAQ:FONR) is the third most undervalued diagnostic & research stock based on WallStreetZen's Valuation Score. Fonar has a valuation score of 71, which is 53 points higher than the diagnostic & research industry average of 18. It passed 5 out of 7 valuation due diligence checks.

Fonar's stock has gained 6.6% in the past year. It has overperformed other stocks in the diagnostic & research industry by 5 percentage points.

Are diagnostic & research stocks a good buy now?

50% of diagnostic & research stocks rated by analysts are a strong buy right now. On average, analysts expect diagnostic & research stocks to rise by 10.22% over the next year.

What is the average p/e ratio of the diagnostics & research industry?

The average P/E ratio of the diagnostics & research industry is 38.56x.

WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.